通化金马上半年净利增长超三成 正积极推进新药上市

Core Viewpoint - Tonghua Golden Horse (000766) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating a positive trend in financial performance despite a challenging market environment [1][2]. Financial Performance - The company achieved an operating income of 650 million yuan, a year-on-year increase of 0.12% [1]. - The net profit attributable to shareholders was 16.804 million yuan, reflecting a year-on-year growth of 34.77% [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 14.4073 million yuan, showing a substantial increase of 125.07% year-on-year [1]. - Basic earnings per share were reported at 0.02 yuan [1]. Business Operations - Tonghua Golden Horse is engaged in the research, production, and sales of pharmaceutical products, with a business unit cluster that includes its headquarters, Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1]. - The company’s product range covers various therapeutic areas, including oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1]. Research and Development - The company is focused on enhancing professional skills and quality research levels, aiming to improve its technological innovation capabilities and market influence [2]. - A self-developed national class 1.1 new drug, Succinic Dihydroaminoacridine Tablets, has received an acceptance notice from the National Medical Products Administration (NMPA) [2]. - The drug, which has complete independent intellectual property rights, is intended for the treatment of mild to moderate Alzheimer's disease and has completed phase III clinical trials from August 2017 to September 2023 [2]. Regulatory Process - The company is actively working on the new drug's registration application in compliance with NMPA regulations and guidelines [2]. - The approval process for the drug involves several uncertainties, including review timelines and market competition dynamics [2]. - The company is maintaining communication with the NMPA during the review process, which is described as a normal state for new drug evaluations [3].